Inhibrx Biosciences, INC 8-K filings

Inhibrx Biosciences has amended its loan agreement with Oxford Finance, increasing its credit facility to $500 million to support its clinical pipeline.

Inhibrx Biosciences announced the FDA has accepted its Biologics License Application for ozekibart (INBRX-109) for the treatment of conventional chondrosarcoma, with a PDUFA goal date of April 14, 2027.

Inhibrx Biosciences, Inc. held its 2026 Annual Meeting of Stockholders, where directors were elected and the appointment of its independent registered public accounting firm was ratified.

Inhibrx Biosciences announced its first quarter 2026 financial results, highlighting progress in its clinical pipeline and a strengthened cash position.

Inhibrx Biosciences announced positive interim Phase 2 data for INBRX-106 in first-line head and neck cancer, showing a significant increase in objective response rates when combined with pembrolizumab.

Inhibrx Biosciences, Inc. announced its financial results for the fiscal year 2025, highlighting a significant reduction in operating expenses and progress in its clinical programs for ozekibart and INBRX-106.

Inhibrx Biosciences, Inc. updated investors on its corporate strategy and clinical pipeline, showcasing positive data for ozekibart in chondrosarcoma and INBRX-106 in oncology, alongside key financial highlights.

Inhibrx Biosciences provided progress updates on its INBRX-106 program for HNSCC and NSCLC, and its ozekibart program for colorectal cancer and Ewing sarcoma, with key data readouts and regulatory discussions anticipated in 2026.

Inhibrx Biosciences announced positive topline results for ozekibart in chondrosarcoma and reported a reduced net loss for the third quarter of 2025.

Inhibrx Biosciences announced positive topline results from its registrational trial of ozekibart in chondrosarcoma, along with encouraging updates for colorectal cancer and Ewing sarcoma cohorts.

Inhibrx Biosciences reported a net loss of $28.7 million in Q2 2025, with significant reductions in operating expenses, and anticipates key clinical trial data readouts for ozekibart and INBRX-106 by late October and Q4 2025, respectively.

Inhibrx Biosciences, Inc. announced the successful completion of its 2025 Annual Meeting of Stockholders, where key governance matters including director elections and auditor ratification were approved.

Inhibrx Biosciences announced its Q1 2025 financial results, highlighting progress in its clinical trials and upcoming data readouts.

Inhibrx Biosciences appoints David Matly as President, while Brendan Eckelman resigns as Chief Scientific Officer to start his own biotech venture.

Inhibrx Biosciences reports its Q4 and FY 2024 financial results, highlighting clinical trial data for ozekibart and a new $100 million loan agreement with Oxford Finance LLC.

Inhibrx Biosciences reported positive preliminary results from a Phase 1 trial of ozekibart in combination with FOLFIRI for advanced colorectal cancer, showing encouraging disease control and responses.

Inhibrx Biosciences has entered into a loan agreement with Oxford Finance for a term loan facility of up to $150 million to bolster strategic flexibility.

Inhibrx Biosciences announced its third quarter 2024 financial results, highlighting ongoing clinical trials and upcoming data readouts.

Inhibrx Biosciences has secured a legal victory in a trade secrets case against I-Mab Biopharma, with the jury rejecting all allegations of misappropriation.

Inhibrx Biosciences announced its second quarter 2024 financial results, highlighted by a significant net income due to the separation from its former parent company and ongoing clinical program advancements.

Inhibrx Biosciences has released an updated corporate presentation highlighting the progress of its clinical programs and financial status.

Inhibrx Biosciences, Inc. has completed its spin-off from Inhibrx, Inc., issuing warrants and entering into several key agreements to establish its independent operations.

Inhibrx Biosciences, Inc. is set to become an independent public company on May 29th, following a spin-off from Inhibrx, Inc., with a merger of Inhibrx, Inc. with Sanofi expected the following day.